Trials / Completed
CompletedNCT00481728
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
Evaluation of Sympathetic Skin Responses and Heart Rate Variability as Objective Measures of Bladder Sensation - a Double Blind Third Party Open Placebo Controlled Randomised Study Using a Single Dose of Tolterodine in Patients With Idiopathic Overactive Bladder and Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Measuring sympathetic skin response or heart rate variability can provide an objective biomarker of bladder sensation and its modulation by drug with potential to treat overactive bladder.
Detailed description
Evaluation of the link between bladder sensation and changes in skin electrical conductance and heart rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolterodine | Single dose per patient as determined by protocol. |
| PROCEDURE | Filling cystometry | This is a procedure. |
| PROCEDURE | Intravesical neurostimulation | This is a procedure. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-06-04
- Last updated
- 2021-01-27
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00481728. Inclusion in this directory is not an endorsement.